论文部分内容阅读
[目的]探讨Stathmin在胃癌中的表达及与多西他赛化疗疗效关系。[方法]应用免疫组化法分析Stathmin在胃癌及癌旁组织中的表达情况,研究其与胃癌临床病理特征的关系;研究Stathmin表达与术后辅助DC(多西他赛+顺铂)方案化疗有效率、临床获益率、1年生存率、3年生存率之间的关系。[结果]胃癌组织Stathmin表达较癌旁组织增高(P<0.05),与胃癌组织分化程度、浸润深度、有无淋巴结转移及临床分期均相关(P<0.05),而与患者的年龄、性别无关;Stathmin过表达较低表达患者化疗敏感性下降(P<0.05),1年生存率、3年生存率尚无统计学意义(P>0.05)。[结论]Stathmin表达与胃癌组织的生物学行为相关;胃癌组织中Stathmin蛋白的表达与患者对含多西他赛化疗方案的敏感性有关,但对生存时间的影响证据尚不足。
[Objective] To investigate the expression of Stathmin in gastric cancer and its relationship with the efficacy of docetaxel chemotherapy. [Method] The expression of Stathmin in gastric cancer and paracancerous tissues was analyzed by immunohistochemistry and its relationship with the clinicopathological features of gastric cancer. The relationship between Stathmin expression and postoperative adjuvant DC (docetaxel + cisplatin) chemotherapy Efficiency, clinical benefit rate, 1-year survival rate, 3-year survival rate. [Results] The expression of Stathmin in gastric cancer was significantly higher than that in paracancerous tissues (P <0.05), but not with the age, sex of patients, and the degree of invasion, depth of invasion, lymph node metastasis and clinical stage (P <0.05) (P <0.05). The 1-year survival rate and 3-year survival rate were not significantly different between patients with Stathmin overexpression and low expression (P> 0.05). [Conclusion] The expression of Stathmin is correlated with the biological behavior of gastric cancer. The expression of Stathmin in gastric cancer is related to the sensitivity of patients to docetaxel chemotherapy regimen, but the evidence of its effect on survival time is still insufficient.